0.85Open0.85Pre Close0 Volume12 Open Interest5.00Strike Price0.00Turnover63.00%IV-0.73%PremiumDec 20, 2024Expiry Date0.88Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8990Delta0.3224Gamma4.58Leverage Ratio-0.0023Theta-0.0016Rho-4.11Eff Leverage0.0017Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet